| 1 |
35061047 | Loncastuximab tesirine: an effective therapy for relapsed or refractory diffuse large B-cell lymphoma. | 2022 May |
1 |
| 2 |
35580172 | THE ANTIBODY-DRUG CONJUGATE LONCASTUXIMAB TESIRINE FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA. | 2022 May 17 |
1 |
| 3 |
33211842 | Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. | 2021 May 13 |
1 |
| 4 |
33989558 | Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. | 2021 Jun |
1 |
| 5 |
32012214 | Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia. | 2020 Feb 11 |
2 |
| 6 |
31685491 | A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. | 2019 Dec 1 |
1 |
| 7 |
29298756 | ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies. | 2018 Mar 8 |
1 |